Concepedia

Mauricio Burotto

MB

Statistics

Publications

60

Citations

6.2K

H-Index

30

Active since

2001

Affiliations

Bristol-Myers Squibb (United States)(Current)

Dana-Farber Cancer Institute

Institut Gustave Roussy

Queen Mary University of London

Memorial Sloan Kettering Cancer Center

Mauricio Burotto is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and urology.

ORCID

Top concepts

Publications per year

2001–2025

60

Publications

60

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Pseudoprogression and Immune-Related Response in Solid Tumors

Victoria L. Chiou, Mauricio Burotto · Journal of Clinical Oncology · 2015 · 882 citations · Full text

, , +13

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Laurence Albigès, Nizar M. Tannir, Mauricio Burotto et al. · ESMO Open · 2020 · 515 citations · Full text

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles et al. · New England Journal of Medicine · 2023 · 421 citations · Full text

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto et al. · The Lancet Oncology · 2022 · 286 citations · Full text

, , +10

1–5 of 60